VG-201 is under clinical development by Virogin Biotech and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how VG-201’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

VG-201 overview

VG-201 is under development for the treatment of CEA high solid tumors. It is administered through parenteral route as injection. The therapeutic candidate is an oncolytic virus with payloads IL12 and IL15/IL15Ralpha. It is developed based on Transcription and Translation Dual Regulated (TTDR) oncolytic virus platform.

Virogin Biotech overview

Virogin Biotech is pharmaceutical company. It focuses on developing immunotherapies and oncolytic virotherapies that improve systemic antitumor immunity. The company is investigating VG161 peptide to treat solid tumors; VG201 and VG301 drugs against carcinoembryonic antigen (CEA) high tumors. It is also evaluating VG202 for the treatment hepatocellular carcinoma; and VG204 drug targeting glioblastoma. Virogin Biotech utilizes its proprietary Synerlytic platform technology to create antitumor immunotherapies. The company works in collaboration with research institutes, biotechnology, and pharmaceutical companies. It operates a research and development hubs in Vancouver, Canada; and Shanghai, China. Virogin Biotech is headquartered in Vancouver, British Colombia, Canada.

For a complete picture of VG-201’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.